Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.49 |
| ▸ | USP30 | Q70CQ3 | 4/20 | 0.49 |
| ▸ | LCK | P06239 | 7/20 | 0.44 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.43 |
| ▸ | OTUD7B | Q6GQQ9 | 1/20 | 0.42 |
| ▸ | ITK | Q08881 | 5/20 | 0.42 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6125718 | 1.00 | KDR (0.49) | KDRUSP30LCKPCSK9OTUD7B | |
| SCHEMBL29470482 | 0.98 | KDR (0.52) | KDRUSP30LCKPCSK9OTUD7B | |
| SCHEMBL6125675 | 0.98 | KDR (0.52) | KDRUSP30LCKPCSK9OTUD7B | |
| SCHEMBL8739127 | 0.97 | KDR (0.51) | KDRUSP30LCKPCSK9OTUD7B | |
| SCHEMBL20461981 | 0.92 | USP30 (0.47) | KDRUSP30LCKPCSK9OTUD7B | |
| SCHEMBL20461980 | 0.90 | TBK1 (0.48) | KDRUSP30LCKPCSK9OTUD7B | |
| SCHEMBL8739542 | 0.89 | LCK (0.45) | KDRUSP30LCKPCSK9ITK | |
| SCHEMBL20055933 | 0.88 | KDR (0.47) | KDRUSP30LCKTBK1 | |
| SCHEMBL29470485 | 0.88 | KDR (0.57) | KDRUSP30LCKITKROCK2 | |
| SCHEMBL15673350 | 0.88 | KDR (0.57) | KDRUSP30LCKITKROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11773110-B2 | Heterocycle amines and uses thereof | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2023-10-03 | — | — | US | disclosed |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11773110-B2 | Heterocycle amines and uses thereof | HNMT, NQO1, ACHE | KDR 4125/4885USP30 4536/4885LCK 212/4885 |
| US-20220119413-A1 | HETEROCYCLE AMINES AND USES THEREOF | HNMT, NQO1, ACHE | KDR 4125/4885USP30 4536/4885LCK 212/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.